About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT06800885

Repeated Cross Sectional Surveillance Study To Determine the Influenza Vaccination Rates in German Participants

Real-time monitoring of vaccination rates for Germany is unavailable, and up-to-date data publication is delayed, which makes it challenging to develop effective public health strategies to increase v...

Lead sponsor: Sanofi Pasteur, a Sanofi Company•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Sanofi Pasteur, a Sanofi Company

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Reside in Germany at the time of survey completion
•Be at least 18 years old at the time of survey completion.
•Agree with privacy policy and AE (Adverse Event) reporting requirements before proceeding with the survey.
•Read and agree to the ICF (Informed Consent Form) by ticking a box before proceeding with the survey or telephone interview.

Exclusion Criteria

•Participation in the study (= completed the survey or telephone interview) in a previous wave of the current season.
•Living in nursing home Note: The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Related studies

Active Not RecruitingPhase 1/2

Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older

NCT06907511 · Pandemic Influenza Immunization, Healthy Volunteers

COMPLETEDPhase 1

Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older

NCT05426174 · Influenza Immunization, Healthy Volunteers

COMPLETEDPhase 3

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older

NCT04024228 · Influenza Immunization, Healthy Volunteers

COMPLETEDPhase 1/2

A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

NCT06361875 · Influenza Immunization

COMPLETEDPhase 1/2

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

NCT05624606 · Influenza Immunization

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 5, 2026Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment5,000

Start dateOct 2024

Last updatedMar 5, 2026

Condition

Influenza Immunization

Locations shown

Germany

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 5, 2026Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions